NCT06461624View on ClinicalTrials.gov

Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

October 31, 2027

Conditions
Advanced Hepatocellular Carcinoma
Interventions
BIOLOGICAL

anti-GPC3 CAR-T

All subjects were intravenous administrated with CBG166.

Trial Locations (2)

310003

RECRUITING

First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou

310009

RECRUITING

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Carbiogene Therapeutics Co. Ltd.

INDUSTRY

lead

Zhejiang University

OTHER